✦ LIBER ✦

Where to go with new expensive treatments in NSCLC

✍ Scribed by Webb, A; O'Brien, MER

Book ID: 109838551
Publisher: Nature Publishing Group
Year: 1998
Tongue: English
Weight: 715 KB
Volume: 78
Category: Article
ISSN: 0007-0920
DOI: 10.1038/bjc.1998.458

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Where to go next with neuroprotection in

Where to go next with neuroprotection in multiple sclerosis?

✍ Franz Fazekas 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 49 KB

Treatment options in end-stage heart fai

Treatment options in end-stage heart failure: where to go from here?

✍ M. L. A. Haeck; G. E. Hoogslag; S. F. Rodrigo; D. E. Atsma; R. J. Klautz; E. E. 📂 Article 📅 2011 🏛 Bohn Stafleu van Loghum 🌐 English ⚖ 464 KB

Examples of implementation and evaluatio

Examples of implementation and evaluation of treatment fidelity in the BCC studies: Where we are and where we need to go

✍ Barbara Resnick; Albert J. Bellg; Belinda Borrelli; Carol De Francesco; Rosemary 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 83 KB

Discussion: Newer bisphosphonates in the

Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go

✍ Andreas Grauer; Henry Bone; Eugene V. Mccloskey; Michael Mcclung; Donald H. Gutt 📂 Article 📅 1999 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 569 KB

The prevention and treatment of infectio

The prevention and treatment of infectious disease in the transplant patient: where are we now and where do we need to go?

✍ R.H. Rubin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 46 KB

Delay in seeking treatment by patients w

Delay in seeking treatment by patients with stroke: Who decides, where they go, and how long it takes

✍ Daniel Geffner; Cristina Soriano; Teresa Pérez; Carlos Vilar; David Rodríguez 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 261 KB